Trans-Tasman Radiation Oncology Group

Trans-Tasman Radiation Oncology Group
Name	Trans-Tasman Radiation Oncology Group
Abbreviation	TROG
Formation	1990s
Headquarters	Australia
Region served	Australia and New Zealand
Membership	radiation oncologists, medical physicists, radiation therapists

Trans-Tasman Radiation Oncology Group is a cooperative clinical trials group focused on radiation oncology research across Australia and New Zealand, linking academic, hospital, and professional institutions. It conducts multicentre randomized trials, prospective cohort studies, and quality assurance programs to improve outcomes in prostate cancer, breast cancer, lung cancer, and other malignancies. TROG’s work interfaces with national health agencies, professional colleges, and international consortia to translate research into clinical practice.

History

TROG was established to coordinate multicentre radiation oncology trials across Australia, New Zealand, and the broader Trans-Tasman region, emerging alongside networks such as the Australasian Leukaemia & Lymphoma Group, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, and the Australian Cancer Trials infrastructure. Early collaborations involved institutions like the Peter MacCallum Cancer Centre, Royal Brisbane and Women’s Hospital, and Auckland City Hospital, and aligned with regulatory environments shaped by bodies such as the Therapeutic Goods Administration, Health New Zealand, and national ethics committees. Over time TROG developed data management and radiotherapy quality assurance systems comparable to international groups including the Radiation Therapy Oncology Group and the European Organisation for Research and Treatment of Cancer.

Organization and Membership

TROG’s governance includes an executive committee, scientific advisory panels, and trial-specific steering committees drawing members from the Royal Australasian College of Physicians, Royal Australasian College of Radiologists, Royal College of Radiologists, and academic departments at universities such as the University of Melbourne, University of Sydney, University of Auckland, and the University of Otago. Membership spans radiation oncologists, medical physicists, radiation therapists, statisticians from institutions like the George Institute for Global Health and trial coordinators linked to the National Health and Medical Research Council and university research offices. Affiliate relationships exist with professional societies including the Australasian College of Physical Scientists and Engineers in Medicine, Clinical Oncology Society of Australia, and the New Zealand Institute of Medical Radiation Technology.

Clinical Trials and Research Programs

TROG designs and runs randomized controlled trials, phase II studies, and observational registries, with methodological input from statisticians formerly associated with the Commonwealth Scientific and Industrial Research Organisation and trial conduct support from clinical trial units at the Peter MacCallum Cancer Centre, St Vincent’s Hospital Melbourne, Royal Hobart Hospital, and Christchurch Hospital. Trials address modalities such as external beam radiotherapy, intensity-modulated radiotherapy used in protocols originating from the MD Anderson Cancer Center paradigm, stereotactic body radiotherapy influenced by protocols from the Mayo Clinic, and brachytherapy consistent with practice at the Memorial Sloan Kettering Cancer Center. Data linkage efforts have incorporated cancer registries like the Australian Cancer Database and the New Zealand Cancer Registry.

Key Studies and Contributions

TROG has led landmark studies affecting fractionation schedules, toxicity reduction, and combined-modality treatment in malignancies treated with radiation, informing practice guidelines also referenced by the National Comprehensive Cancer Network and the European Society for Radiotherapy and Oncology. Notable contributions include trials refining hypofractionation in prostate cancer similar to studies at University College London and Erasmus University Medical Center, trials on accelerated partial-breast irradiation paralleling protocols from the European Institute of Oncology, and lung cancer stereotactic trials aligning with work at the University of Texas MD Anderson Cancer Center. TROG publications have appeared in journals such as the Lancet Oncology, Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics, and Radiotherapy and Oncology and have been cited by guideline-setting bodies including the Australian Commission on Safety and Quality in Health Care.

Funding and Collaborations

TROG secures funding from national research bodies such as the National Health and Medical Research Council, philanthropic organizations like Cancer Council Australia and the Cancer Society of New Zealand, and grants from state health departments and university research offices at institutions including the University of Adelaide and the University of Western Australia. Collaborative partnerships extend to industry sponsors, equipment manufacturers exemplified by Varian Medical Systems and Elekta AB, and international cooperative groups including the Radiation Therapy Oncology Group, European Organisation for Research and Treatment of Cancer, and the Trans-Tasman Radiation Oncology Group’s academic collaborators at the Fred Hutchinson Cancer Research Center and the Cancer Research UK network. TROG has also worked with the Australian Clinical Trials Alliance for trial governance and the International Atomic Energy Agency on radiotherapy safety standards.

Impact on Oncology Practice and Policy

TROG’s trials have influenced clinical pathways used in tertiary centers such as the Royal Prince Alfred Hospital and Flinders Medical Centre, contributed to national clinical guidelines promulgated by agencies like the Australian Health Practitioner Regulation Agency, and informed reimbursement and policy discussions involving health ministries in Canberra and Wellington. The group’s quality assurance programs and technical standards have been integrated into training curricula at the University of Sydney and continuing professional development frameworks of the Royal Australasian College of Radiologists and have supported evidence-based changes adopted by oncology services in regional hospitals such as the Sunshine Coast University Hospital and Waikato Hospital.

Category:Radiation oncology Category:Medical research organizations in Australia Category:Medical research organizations in New Zealand